ソレイジア・ファーマ(株)
株価チャート
2026/08/21 更新株価トレンド
2026/08/21 更新株価・取引詳細
2026/08/21 更新株価
取引
株主構成
2026/08/01 更新財務パフォーマンス
2026/08/23 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥11億 | ¥6億 | ¥3億 | ¥4億 |
| 売上総利益 | ¥7億 | ¥3億 | ¥2億 | ¥2億 |
| 営業利益 | -¥25億 | -¥11億 | -¥20億 | -¥9億 |
| 経常利益 | -¥25億 | -¥11億 | -¥20億 | -¥9億 |
| 当期純利益 | -¥25億 | -¥11億 | -¥19億 | -¥9億 |
| EPS | -¥16.77 | -¥6.62 | -¥8.90 | -¥3.33 |
| 営業利益率 | -226.28% | -184.60% | -617.09% | -200.47% |
| 貸借対照表 | ||||
| 総資産 | ¥31億 | ¥22億 | ¥14億 | ¥21億 |
| 純資産 | ¥27億 | ¥19億 | ¥10億 | ¥16億 |
| 総負債 | ¥5億 | ¥4億 | ¥3億 | ¥5億 |
| 現金 | ¥8億 | ¥7億 | ¥9億 | ¥14億 |
| 有利子負債 | ¥0億 | ¥1億 | ¥0億 | ¥0億 |
| 自己資本比率 | 84.94% | 84.07% | 76.33% | 77.96% |
| D/Eレシオ | 0.01 | 0.03 | 0.01 | 0.01 |
| キャッシュフロー | ||||
| 営業CF | -¥21億 | -¥4億 | -¥10億 | - |
| 投資CF | -¥4億 | - | - | - |
| 財務CF | ¥26億 | ¥3億 | ¥12億 | - |
| フリーCF | -¥25億 | -¥4億 | -¥10億 | - |
| 効率性 | ||||
| ROE | -95.72% | -59.34% | -187.54% | -54.07% |
| ROA | -81.30% | -49.89% | -143.14% | -42.16% |
最新IR情報
最新ニュース (5件)
企業情報
会社概要
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
